Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
36112968
DOI
10.1182/blood.2022016963
PII: S0006-4971(22)01278-2
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute * drug therapy etiology MeSH
- Cytarabine MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Antineoplastic Combined Chemotherapy Protocols MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cytarabine MeSH
Almazov National Medical Research Center Saint Petersburg Russia
Centre Hospitalier Le Mans Le Mans France
Chinese Academy of Medical Sciences Tianjin China
CIUSSS EMTL Installation Maisonneuve Rosemont Montreal Quebec City Canada
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX
Eastern Health and Monash University Melbourne Victoria Australia
Evaggelismos General Hospital Athens Greece
George Papanicolaou General Hospital Thessalonica Greece
Heartlands Hospital Birmingham United Kingdom
Hubertus Wald University Cancer Center University Medical Center Hamburg Eppendorf Hamburg Germany
National and Kapodistrian University of Athens Medical School Laiko General Hospital Athens Greece
Netcare Pretoria East Hospital Moreletapark Pretoria South Africa
Norton Cancer Institute Louisville KY
Seoul National University Hospital Seoul Republic of Korea
University of Fukui Hospital Fukui Japan
University of Pittsburgh Medical Center Cancer Center Pittsburgh PA
References provided by Crossref.org
